Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Shiozaki Asks for Early Enactment of Clinical Research Bill
Health Minister Yasuhisa Shiozaki on October 19 asked the Diet to promptly enact a bill for the legal regulation of clinical research, which has been deliberated by the parliament since earlier this year. “To promote the implementation of proper clinical…
To read the full story
Related Article
- Clinical Research Bill Unlikely to Clear Extra Diet
December 5, 2016
- Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
REGULATORY
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- MHLW to Hear Patient Groups on OTC-Like Drug Charge Exemptions
July 27, 2026
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
- MHLW Unveils Preventive Healthcare Plan Focused on Dementia, Other Areas
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…